000518.SZ
四环生物
SZSE · Healthcare · C 制造业 · CN
CNY 3.70
−2.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 381.7M | 344.4M | 203.5M | 235.4M | 270.1M |
| Cost of Revenue | 265.9M | 215.9M | 75.9M | 71.2M | 78.2M |
| Gross Profit | 115.8M | 128.5M | 127.6M | 164.2M | 191.9M |
| Operating Expenses | |||||
| R&D Expense | 25.4M | 32.5M | 29.0M | 29.2M | 39.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 53.8M | 62.0M | 64.9M | 67.0M | 65.1M |
| Selling & Marketing Expense | 65.5M | 63.8M | 67.7M | 116.6M | 125.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 148.0M | 161.5M | 165.1M | 216.5M | 233.0M |
| Cost and Expenses | 414.0M | 377.5M | 241.1M | 287.7M | 311.2M |
| Operating Income (EBIT) | (38.5M) | (40.5M) | (78.9M) | (76.6M) | (54.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (36.3M) | (40.9M) | (113.7M) | (79.4M) | (53.6M) |
| Income Tax Expense | (1.5M) | (1.3M) | 73.8K | 989.4K | (325.4K) |
| Bottom Line | |||||
| Net Income | (32.5M) | (37.1M) | (110.0M) | (75.3M) | (48.8M) |
| Earnings from Cont. Ops | (34.7M) | (39.6M) | (113.8M) | (80.4M) | (53.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.5M) | (37.1M) | (110.0M) | (75.3M) | (48.8M) |
| Per Share | |||||
| Basic EPS | (CN¥0.03) | (CN¥0.04) | (CN¥0.11) | (CN¥0.07) | (CN¥0.05) |
| Diluted EPS | (CN¥0.03) | (CN¥0.04) | (CN¥0.11) | (CN¥0.07) | (CN¥0.05) |
| Revenue Per Share | CN¥0.37 | CN¥0.33 | CN¥0.20 | CN¥0.23 | CN¥0.26 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Diluted Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | (28.1M) | (62.9M) | (57.3M) | (34.5M) |
| D&A | — | 12.5M | 15.9M | 19.2M | 19.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026